Pharmafile Logo

Kraeber (UK) Ltd

The family owned business, Kraeber & Co GmbH, is an independent, technology based enterprise which was founded on the 1st January 1980 in Hamburg. Hanseatic tradition together with courageous entrepreneurship characterize our company. We are committed to open and global competition which we stand up with our service capabilities. Our emphasis is the development, production, marketing and sales of active pharmaceutical ingredients (APIs) of the highest purity. Kraeber has evolved into a niche marketer and supplier. By continously innovating productions, we became the quality market leader in Europe and in other parts of the world for many of our products.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

16 The Street, Saxon Street, Newmarket, Suffolk, CB8 9RU, United Kingdom
+44 (0)1638 731 297

 Latest Content from PMHub 

OPEN Health has been awarded a Bronze Medal by EcoVadis

We are delighted to announce that OPEN Health has been awarded a Bronze Medal by EcoVadis for its very first Corporate Social Responsibility assessment in recognition of its commitment to Corporate Social...

In the precision medicine era, the line between products and services is blurred

Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?

Leveraging Data, Technology & Expertise to Solve Problems & Transform Healthcare

Videos and Podcasts | September 3, 2020 | Impetus Digital

Tushar Pant, Consulting Executive in Healthcare at IBM, discusses how technology is transforming healthcare. Among many other things, we explore how IBM is working to improve the healthcare industry in Canada,...

Reimagining Healthcare Through Integrated Digital Health Empowerment

Videos and Podcasts | September 3, 2020 | Impetus Digital

Yianni Serpanos, Founder & CEO of HealthTechX, discusses a variety of topics, including how COVID-19 has affected the uptake of telehealth among allied health professionals in Australia and worldwide. Yianni also...

Porterhouse Medical Hub, Nottingham: The latest development for the Porterhouse Medical Group

As part of our continued expansion and the expansion of imc group, Porterhouse Medical Group, global insight-led scientific and medical communications agency, is delighted to announce the opening of our latest...

Digital Therapeutics Landscape in Europe

OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK

Live webinar from Singapore

White Papers and Resources | September 2, 2020 | Inizio

Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19

OPEN Health’s virtual reflections on the World Orphan Drug Congress US

Another congress attended in this virtual world with learnings gathered and connections made across the rare disease community. It was great to be joined by many colleagues from all our...

Guide

White Papers and Resources | September 1, 2020 | Inizio

UX research

Article: Why pharma must trust the science of behaviour

White Papers and Resources | September 1, 2020 | Inizio

In a recent interview with PME Magazine, Dan Coffin, Director explains why the application of behavioural science will be key to better health far beyond COVID-19.Read the full article here:...